Skip to main content

Table 2 Comparison of outcomes between early infliximab induction and delayed infliximab induction groups

From: Combined therapy with early initiation of infliximab following drainage of perianal fistulising Crohn’s disease: a retrospective cohort study

Characteristics Early infliximab induction (n = 73) Delayed infliximab induction (n = 44) p value
Duration of follow-up, months (IQR) 32.0 (21.0–60.5) 37.5 (33.5–57.25) 0.021
Initial surgery, n (%)    0.001
 Seton drainage 70 (95.9) 33 (75.0) 0.001
 Fistulotomy 2 (2.7) 8 (18.2) 0.011
 RAF 0 (0) 2 (4.5) 0.296
 LIFT 1 (1.4) 1 (2.3) 1.000
Medical treatment at last follow-up, n (%)    0.761
 Infliximab 10 (13.7) 3 (6.8) 0.524
 Immunomodulators 33 (45.2) 21 (47.7) 0.979
 5-ASA 4 (5.5) 3 (6.8) 0.934
 None 26 (35.6) 17 (38.6) 0.743
Re-intervention, n (%) 25 (34.2) 11 (25.0) 0.294
Fistula healing, n (%) 45 (61.6) 29 (65.9) 0.643
Re-intervention-free healing rate, n (%) 33 (45.2) 24 (54.6) 0.328
  1. IQR interquartile range, RAF rectal advancement flap, LIFT ligation of the intersphincteric fistula tract, 5-ASA 5-aminosalicylic acid